AR070268A1 - Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende - Google Patents

Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende

Info

Publication number
AR070268A1
AR070268A1 ARP090100249A ARP090100249A AR070268A1 AR 070268 A1 AR070268 A1 AR 070268A1 AR P090100249 A ARP090100249 A AR P090100249A AR P090100249 A ARP090100249 A AR P090100249A AR 070268 A1 AR070268 A1 AR 070268A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
haloalkoxy
haloalkyl
cyano
Prior art date
Application number
ARP090100249A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0801597A external-priority patent/GB0801597D0/en
Priority claimed from GB0819112A external-priority patent/GB0819112D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR070268A1 publication Critical patent/AR070268A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos utiles para el tratamiento y/o profilaxis de trastornos de la alimentacion, tales como la obesidad. Reivindicacion 1: Un compuesto de oxa-azaspiro caracterizado porque es de la formula (1) o una sal farmacéuticamente aceptable del mismo, en la que R es un arilo o heteroarilo, que puede estar sustituido con uno o más halogeno, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4 o ciano; Z1 es H, alquilo C1-4 o F; Z es CH2, CH(alquilo C1-4), C(alquilo C1-4)2 o un enlace; A es un arilo o heteroarilo de 6-10 miembros, que puede estar sustituido con uno o más halogeno, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4 o ciano; o C(=O)-X; o -O(CH2)0-1R1; B es hidrogeno o es un heteroarilo de 5-6 miembros, o un heterociclo de 4-6 miembros, o fenilo, que puede estar sustituido con uno o más halogeno, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4, hidroxilo, ciano; donde A y B están unidos mediante cualquier átomo; R1 es -alquil C1-4-alcoxi C1-4; o cicloalquilo C3-8; o R1 es un arilo o heteroarilo, que puede estar sustituido con uno o más halogeno, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4 o ciano; o R1 es un heterociclo de 4-6 miembros, que puede estar sustituido con uno o más halogeno, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4 o ciano; X es OR2 o NR3R4; R2 es alquilo C1-4; R3 es hidrogeno o junto con R4 y el átomo de nitrogeno forma un anillo saturado de 5-6 miembros; R4 es cicloalquilo C3-8.
ARP090100249A 2008-01-29 2009-01-27 Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende AR070268A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0801597A GB0801597D0 (en) 2008-01-29 2008-01-29 Chemical compounds
GB0819112A GB0819112D0 (en) 2008-10-17 2008-10-17 Chemical compounds

Publications (1)

Publication Number Publication Date
AR070268A1 true AR070268A1 (es) 2010-03-25

Family

ID=40456386

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100249A AR070268A1 (es) 2008-01-29 2009-01-27 Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende

Country Status (7)

Country Link
US (1) US20090203705A1 (es)
AR (1) AR070268A1 (es)
CL (1) CL2009000171A1 (es)
PE (1) PE20091324A1 (es)
TW (1) TW200944520A (es)
UY (1) UY31619A1 (es)
WO (1) WO2009095377A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370829T3 (es) * 2004-06-02 2011-12-23 Sandoz Ag Producto intermedio de meropenem en forma cristalina.
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
WO2007053427A2 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
ES2442257T3 (es) * 2006-10-27 2014-02-10 Signal Pharmaceuticals Llc Formas sólidas que comprenden 4-[9-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-ciclohexan-1-ol, sus composiciones y sus usos
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2012030957A2 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
US9487507B2 (en) * 2011-06-17 2016-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists
ES2595606T3 (es) * 2011-06-17 2017-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Antagonistas TRPV4
JO3154B1 (ar) * 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
CN107810188B (zh) 2015-04-08 2020-09-22 拜耳作物科学股份公司 作为害虫防治剂和中间体产物的稠合双环杂环衍生物
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Pde10インヒビターならびに関連する組成物および方法
EP3896066A3 (de) 2015-08-07 2021-12-08 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel
CN108430986B (zh) 2015-10-26 2021-08-31 拜耳作物科学股份公司 作为有害生物控制剂的稠合双环杂环衍生物
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2017174414A1 (de) 2016-04-05 2017-10-12 Bayer Cropscience Aktiengesellschaft Naphthalin-derivate als schädlingsbekämpfungsmittel
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2017199199A1 (en) * 2016-05-19 2017-11-23 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonist
JP6967064B2 (ja) 2016-07-19 2021-11-17 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 有害生物防除剤としての縮合二環式ヘテロ環誘導体
PE20190800A1 (es) 2016-08-15 2019-06-10 Bayer Cropscience Ag Derivados del heterociclo biciclico condensado como agentes de control de plagas
CN109789132A (zh) * 2016-08-29 2019-05-21 德州大学系统董事会 用于治疗疾病的双亮氨酸拉链(dlk)激酶抑制剂
CN109963860A (zh) 2016-09-19 2019-07-02 拜耳作物科学股份公司 吡唑并[1,5-a]吡啶衍生物及其作为农药的用途
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
WO2018107072A1 (en) 2016-12-08 2018-06-14 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
EP3568392B1 (de) 2017-01-10 2021-02-24 Bayer Aktiengesellschaft Imidazol-derivate als schädlingsbekämpfungsmittel
KR20230020566A (ko) 2017-01-10 2023-02-10 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
MX2019012728A (es) 2017-04-24 2020-01-23 Bayer Ag Derivados de heterociclos biciclicos fusionados como plaguicidas.
EP3305786A3 (de) 2018-01-22 2018-07-25 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2019162174A1 (de) 2018-02-21 2019-08-29 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US20220204499A1 (en) 2019-02-26 2022-06-30 Bayer Aktiengesellschaft Condensed bicyclic heterocyclic derivatives as pest control agents
WO2020173860A1 (en) 2019-02-26 2020-09-03 Bayer Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
US11485727B2 (en) * 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途
TW202409024A (zh) 2022-07-08 2024-03-01 美商愛克堤歐生物科學公司 治療性化合物及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005030051A1 (de) * 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
AU2007293416A1 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2008092891A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited 1-oxa-3-azaspiro(4.5)decan-2-one derivatives for the treatment of eating disorders
JP2010517966A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の処置のための1−オキサ−3−アザスピロ(4.5)デカン−2−オンおよび1−オキサ−3,8−ジアザスピロ(4.5)デカン−2−オン誘導体
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
EP2280703A1 (en) * 2008-03-12 2011-02-09 Københavns Universitet (University Of Copenhagen) Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse

Also Published As

Publication number Publication date
UY31619A1 (es) 2009-08-31
PE20091324A1 (es) 2009-09-25
TW200944520A (en) 2009-11-01
CL2009000171A1 (es) 2009-11-27
US20090203705A1 (en) 2009-08-13
WO2009095377A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
AR070268A1 (es) Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
AR091710A1 (es) Composiciones pesticidas y procesos relacionados con las mismas
WO2014117076A8 (en) Alkyl aromatic hydroalkylation for the production of plasticizers
AR071055A1 (es) Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas
AR075104A1 (es) Compuesto de piperazin-aril-purina, su uso para preparar un medicamento util para el tratamiento del dolor y composicion farmaceutica que lo comprende
DOP2013000193A (es) Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
MX2010012298A (es) Activadores de glucocinasa.
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
ECSP11010754A (es) Derivados de triazol útiles para el tratamiento de enfermedades
BRPI0821235A2 (pt) Composição de moldagem termoplástica, usos de composto e de composição de moldagem termoplástica, e, fibra, folha, ou uma moldagem.
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
ME00996B (me) Trans-klomifen za liječenje metaboličkog sindroma
IN2014KN01075A (es)
IN2014MN01521A (es)
WO2008099072A3 (fr) Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AR090172A1 (es) Proceso para la preparacion de carboxamidas
ATE517869T1 (de) Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
ECSP13013075A (es) Método de tratamiento de la fiebre dengue
NO20085317L (no) Imidazoazepinonforbindelser
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique

Legal Events

Date Code Title Description
FB Suspension of granting procedure